
Sign up to save your podcasts
Or


Send us Fan Mail
Manal Abdelmalek, Naim Alkhouri, and Akero Therapeutics Chief Development Officer Kitty Yale join the Surfers to discuss Friday's FDA webcast on NASH Drug Development.
Friday's FDA Webcast on NASH drug development provided few concrete answers but several clues and directions to pursue. Listen as Manal Abdelmalek, Naim Alkhouri, and Kitty Yale, Chief Development Officer at Akero Therapeutics, join the Surfers to read the tea leaves and identify fruitful areas for further research and pursuit. Issues around diagnostics and the risk: benefit tradeoff received particular attention.
By SurfingNASH.com3.9
2424 ratings
Send us Fan Mail
Manal Abdelmalek, Naim Alkhouri, and Akero Therapeutics Chief Development Officer Kitty Yale join the Surfers to discuss Friday's FDA webcast on NASH Drug Development.
Friday's FDA Webcast on NASH drug development provided few concrete answers but several clues and directions to pursue. Listen as Manal Abdelmalek, Naim Alkhouri, and Kitty Yale, Chief Development Officer at Akero Therapeutics, join the Surfers to read the tea leaves and identify fruitful areas for further research and pursuit. Issues around diagnostics and the risk: benefit tradeoff received particular attention.

32,106 Listeners

30,684 Listeners

9,625 Listeners

103 Listeners

21,138 Listeners

3,363 Listeners

112,063 Listeners

56,553 Listeners

9,529 Listeners

8,026 Listeners

10,196 Listeners

6,388 Listeners

0 Listeners

426 Listeners

743 Listeners